Jennifer Humes
Fortuna: 4 M $ al 31/08/2026
Fortuna: 4 M $ al 31/08/2026
Jennifer Humes is Chief Accounting Officer at Roivant Sciences Ltd. and Roivant Sciences, Inc., starting in 2025.
Ms. Humes worked at JPMorgan Chase & Co. from 2016 to 2024, serving as Controller-Global Investment Banking in 2024.
Ms. Humes completed undergraduate education at the University of St. Thomas.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ROIVANT SCIENCES LTD. 0,01 % | 20/09/2026 | 106.419 ( 0,01 % ) | 4 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ROIVANT SCIENCES LTD. | Comptroller/Controller/Auditor | 20/02/2025 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Comptroller/Controller/Auditor | 20/02/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | 01/12/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
JPMorgan Chase & Co.
JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
Roivant Sciences Ltd.
Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
University of St. Thomas
University of St. Thomas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.